Infectious Diseases

Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19.   Regeneron is running two trials simultaneously, one for prevention and other for treatment, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Phase III trial is studying if the cocktail antibody has the pre-emptive potential and can prevent the SARS-CoV-2. The drug is also undergoing the Phase II/III portion of two adaptive Phase I/II/III trials that are evaluating REGN-COV2 in treating hospitalized and non-hospitalized patients with COVID-19. REGN-COV2 is the company's cocktail therapy of two most potent, non-comp...